Suppr超能文献

抑制热休克蛋白 90 可使肺腺癌中的受体酪氨酸激酶 ROR1 不稳定。

Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma.

机构信息

Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Division of Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.

出版信息

Cancer Sci. 2021 Mar;112(3):1225-1234. doi: 10.1111/cas.14786. Epub 2021 Jan 27.

Abstract

We have previously identified receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a direct transcriptional target of TTF-1/NKX2-1, a lineage-survival oncogene in lung adenocarcinoma. ROR1 sustains prosurvival signaling from multiple receptor tyrosine kinases including epidermal growth factor receptor, MET, and insulin-like growth factor 1 receptor in part by maintaining the caveolae structure as a scaffold protein of cavin-1 and caveolin-1. In this study, a high throughput screening of the natural product library containing 2560 compounds was undertaken using a cell-based FluoPPI assay detecting ROR1-cavin-1 interaction. As a result, geldanamycin (GA), a known inhibitor of heat shock protein 90 (HSP90), was identified as a potential inhibitor of ROR1. Geldanamycin, as well as two GA derivatives tested in the clinic, 17-allylamino-17-demethoxygeldanamycin (17-AAG) and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), decreased ROR1 protein expression. We found that ROR1 physically interacted with HSP90α, but not with other HSP90 paralogs, HSP90β or GRP94. Geldanamycin in turn destabilized and degraded ROR1 protein in a dose- and time-dependent manner through the ubiquitin/proteasome pathway, resulting in a significant suppression of cell proliferation in lung adenocarcinoma cell lines, for which the kinase domain of ROR1, but not its kinase activity or N-glycosylation, was required. Our findings indicate that HSP90 is required to sustain expression of ROR1 crucial for lung adenosarcoma survival, suggesting that inhibition of HSP90 could be a promising therapeutic strategy in ROR1-positive lung adenocarcinoma.

摘要

我们之前已经鉴定出受体酪氨酸激酶样孤儿受体 1(ROR1)是肺腺癌中转录生存基因 TTF-1/NKX2-1 的直接转录靶点。ROR1 通过作为 cavin-1 和 caveolin-1 的支架蛋白来维持小窝结构,从而维持来自多种受体酪氨酸激酶(包括表皮生长因子受体、MET 和胰岛素样生长因子 1 受体)的促生存信号。在这项研究中,使用基于细胞的 FluoPPI 测定法(检测 ROR1-cavin-1 相互作用)对包含 2560 种化合物的天然产物文库进行了高通量筛选。结果,格尔德霉素(GA),一种已知的热休克蛋白 90(HSP90)抑制剂,被鉴定为 ROR1 的潜在抑制剂。格尔德霉素以及在临床上测试的两种 GA 衍生物,17-烯丙基-17-去甲氧基格尔德霉素(17-AAG)和 17-二甲基氨基乙基氨基-17-去甲氧基格尔德霉素(17-DMAG),降低了 ROR1 蛋白表达。我们发现 ROR1 与 HSP90α 相互作用,但与其他 HSP90 同源物 HSP90β 或 GRP94 不相互作用。格尔德霉素以剂量和时间依赖的方式通过泛素/蛋白酶体途径使 ROR1 蛋白不稳定和降解,从而显著抑制肺腺癌细胞系的增殖,其中 ROR1 的激酶结构域,而不是其激酶活性或 N-糖基化,是必需的。我们的研究结果表明,HSP90 对于维持 ROR1 的表达是必需的,这对于肺腺肉瘤的生存至关重要,这表明抑制 HSP90 可能是 ROR1 阳性肺腺癌的一种有前途的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4faa/7935804/3dc6d87b94bb/CAS-112-1225-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验